Combination Therapy – A Wave of the Future – Combining Provenge & Avastin
We have talked about it many times in past posts, the potential that many believe combination therapy can hold for better treatments for all cancers, including advanced prostate cancer. Combination therapy has made AIDS treatment [...]
At the American Society of Clinical Oncology (ASCO) Meeting
I am attending the 2010 annual meeting of ASCO. There is a lot going on and a lot to see and learn. I am taking notes and will share information, but m schedule will not [...]
Seeking Cures – the Road from Discoveries to Cures or the Valley of Death
It is truly amazing and very shocking, from 1996 to 1999, the U.S. food and Drug Administration (FDA) approved 157 new drugs. Compared to the period of 2006 to 2009 the FDA approved 74 drugs. [...]
On the Horizon – Alpharadin (Radium-223)- A Long Survival Possibility for Men with Castrate Resistant Prostate Cancer
In 2007 a Norwegian cancer therapeutics company, Algeta, presented data from a phase II study that showed a remarkable two-year survival advantage with its investigational drug, Alpharadin (radium-223), when used as a as a treatment [...]
Reported Antitumor Activity of MDV3100 in a Phase 1-2 Study of Advanced Prostate Cancer – A Great Success
At the on-going AUA Meeting, Dr. Howard Scher along with a collaborating group of medical oncologists reported their data from a Phase I-II trial of MDV3100 in castration-resistant prostate cancer (CRPC). […]
The National Comprehensive Cancer Network Updates Best Clinical Practice Guidelines to Include Provenge
The National Comprehensive Cancer Network (NCCN), a private organization which develops what has become the standard of care guidelines for clinical practice in oncology, has modified their guidelines to included sipuleucel-T (Provenge) as a part [...]